Deucravacitinib for Sarcoidosis and Granuloma Annulare
What You Need to Know Before You Apply
What is the purpose of this trial?
To investigate the role of an oral TYK2 inhibitor for the treatment of patients with moderate to severe sarcoidosis with cutaneous involvement (CSAMI score of 10 or greater) and GA (defined as a BSA involvement of at least 5%), which are difficult to treat.
Who Is on the Research Team?
William Damsky, M.D.
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
This trial is for people with moderate to severe sarcoidosis that affects the skin (CSAMI score ≥10) or Granuloma Annulare covering at least 5% of their body. Specific eligibility details are not provided, but typically there would be criteria about overall health and possibly age.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the TYK2 inhibitor deucravacitinib 6mg twice daily for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Deucravacitinib
Deucravacitinib is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania